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INTRODUCTION 
One of the first-line drugs in the therapy of seizure disorders in 
pediatrics is phenobarbital. Frequently it is used alone when seizures 
can be controlled with a single drug, however its use in combination with 
1 2 
other anticonvulsants is also prevalent. ' According to Buchthal, pheno-
barbital should be the first medication tried for grand raal and focal 
seizures and in infants is superior to phenytoin for febrile seizures."*" 
However, psychomotor and petit mal seizures seldom respond and occasion-
ally may be made worse. 
The current literature has a paucity of studies involving phenobar-
bital pharmacokinetics in children between the ages of one to 14 years. 
It has been suggested that their half-life is age-dependent, falling in 
3-5 
the range of 37-133 hours which is comparable to the range reported for 
adults (.53-140 hours^'^). Because of the prolonged half-life, it seems 
reasonable to recommend once daily dosing for children and indeed Living-
2 
ston mentions this possibility. However, Svensmark and Buchthal sug-
gested a twice daily dosage for children based on the assumption that 
8 9 
they maintain an increased rate of elimination of phenobarbital. ' 
These studies have since become the basis for scheduling phenobarbital 
doses for c h i l d r e n . T h e present practice of twice a day dosing of 
phenobarbital based on Svensmark and Buchthal's work is open to question 
because of questionable data interpretation in their report. The purpose 
of this investigation was to evaluate the appropriateness of once daily 
dosing of phenobarbital in children with seizure disorders. 
MATERIALS AND METHODS 
The study design was a controlled crossover method with the population 
7 
consisting of seven outpatients from the Neurology Clinic at Primary 
Children's Medical Center, Salt Lake City, Utah. The study period began 
in November 1979 and ended in March 1980. The range of ages was eight 
months to seven years with three females and four males participating. 
The diagnosis of seizure disorder was based on history and electroencepha-
logram findings and made by the two pediatric neurologist co-investigators. 
There were four patients with a diagnosis of idiopathic epilepsy and three 
with febrile seizures. Patients were from six weeks to three years be-
yond the time of diagnosis and doses of phenobarbital ranged from 2.9 
mg/Kg/day to 6.6 mg/Kg/day. Patients being maintained on multiple anti-
convulsant therapy or other medications for concurrent diseases in addi-
tion to the seizure disorder were excluded from the study. Additional 
exclusions included those patients, parents, and/or guardians who declined 
to participate, and patients who had a history of an adverse reaction to 
phenobarbital or liver and/or kidney disease. 
All patients had been maintained on phenobarbital for a minimum of 
six weeks prior to entering the study. This period of time was felt to 
be adequate for attaining each patients steady state serum concentration, 
which according to Gibaldi and Perrier should be within one per cent of the 
eventual steady state value after the drug has been administered for 
seven drug half-lives.The steady state is defined as the point at 
which a plateau in the serum concentration of a drug is achieved after 
successive dosing signifying that intake and elimination are equal."*""'' 
According to the half-life values for children, this plateau shall be 
reached with phenobarbital approximately twenty-one days from the first 
dose. Upon entering the study, each patient's serum phenobarbital concen-
tration was obtained one hour prior to the dose and analysed by the Enzyme 
8 
Mediated Immunoassay Technique (EMIT) in the chemistry department at 
Primary Children's Medical Center. This assay technique is a homogeneous 
enzyme immunoassay for antiepileptic drugs and is based on competitive 
protein binding concepts using an enzyme as a label and an antibody as a 
12 
specific binding protein. The antiepileptic drug concentrations measured 
with the EMIT system are designed to have a coefficient of variation of 
12 
less than 15%. Each patient was then scheduled to receive either a 
single daily dose or twice daily doses using the same total daily dosage 
of phenobarbital. This schedule was maintained for a minimum of four 
weeks (twenty-eight days) with daily notations by the parents of the 
specific times each dose was administered (Appendix 1). At the end of 
the study period, a second serum phenobarbital concentration was obtained 
again at one hour prior to the dose. Care was taken by the principle 
investigator to assure the correct timing of all serum concentrations 
by visiting the patient's home to obtain serum samples. Measures to 
assure compliance included daily records of times doses were given which 
were kept by the parents, and exact pill counts which were taken prior to 
and at the end of the study with notation of refill prescriptions acknow-
ledged (Appendix 1). Tablets and elixir of phenobarbital were used by 
the patients, however each patient served as his own control and prior 
doses and dosage forms were maintained throughout the study. 
RESULTS 
The results of the study are presented in Table 1 and illustrated 
in Figure 1. Evaluation of the phenobarbital serum concentrations in 
Table 1 illustrates that the intrapatient difference between the two 
regimens did not differ significantly (paired t-Test, p>0.10=0.05) . 
TABLE 1. Clinical and laboratory characteristics of patients with seizure disorders 
Serum Phenobarbital 
Seizure Activity (mg/L) 
Time Phenobarbital 
Weight Since Dose Since During Daily Twice 
Patient Sex Age (Kg) Diagnosis Diagnosis (mg/Kg/day) Diagnosis Study Dosing Daily Dosing 
F 7yr. 22.7 Idiopathic 6 months 
epilepsy 








M 3yr. 15.9 Febrile 2 years 
seizure 
3.8 26 22 
M 4yr. 20.5 Febrile 3 years 
seizure 
2.9 14 13 
M 21 mon. 13.6 Idiopathic 3 months 
epilepsy 
F 3Jgyr. 13.6 Idiopathic 1 year 
epilepsy 



















Days of Regimen 
• = daily dosing 
• = twice daily dosing 
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The absolute mean deviation was 3 mg/L during the dosing interval. Addi-
tional evaluation of the data (Table 2) revealed an average clearance 
value of 0.0089 L/Kg/hr with a standard deviation of 0.0032. The follow-
ing formula was used for calculation of clearance: 
CI, = D X F 
b 
Css X t 
where X = dosing interval, D = dose, F = fraction of drug absorbed, Css = 
13 
mean steady state serum concentration, and Cl^ = total body clearance. 
Svensmark and Buchthal's work indicates that about 80% of phenobarbital 
is absorbed orally with tablets but this value may be even greater with 
elixir and may vary individually,^ therefore 0.80 was used as an average 
fractional absorption (F). The serum phenobarbital concentrations meas-
ured at one hour prior to the dose were substituted for Css. 
No adverse side effects were experienced by the patients nor was 
any seizure activity apparent during the study. One parent stated that 
his child seemed slightly more irritable on twice daily dosing and a 
second child's parent stated the opposite effect. Compliance was re-
corded as greater than 98% based upon evaluation of daily records of 
doses taken and actual pill counts. 
DISCUSSION 
Phenobarbital is the mainstay of therapy in managing pediatric 
seizure disorders. Unfortunately the literature is devoid of extensive 
pharmacokinetic evaluations of phenobarbital in this age group. Svensmark 
and Buchthal attempted to characterize a proper dose needed to maintain 
a range of serum concentrations between 10 mg/L and 20 mg/L with a 
12 





















































































Standard Deviation 0.0032 
13 
8 9 
comparison of dosing to adult data. ' Their conclusions were that when 
proportionate doses for body weight were used in children, aged one to 14 
9 
years, the serum phenobarbital concentrations were lower than in adults. 
They postulated that an increased rate of elimination might explain the 




phenobarbital. This study's recommendations have been accepted with 
respect to dosing phenobarbital in children with seizure disorders. 
For many years, despite reports of similar half-life values in children 
o c 6 7 
(37-133 hours) to those of adults (53-140), ' phenobarbital dosing 
has continued in a twice daily regimen. There are two items of concern 
with the Svensmark and Buchthal study, First, children were included who 
received either phenobarbital singly or in combination with phenytoin 
with no indication of a separation of the two fractions prior to reporting 
the data. Phenobarbital has been shown to stimulate both hepatic metabo-
14 15 lism and biliary excretion of drugs. These two physiologic processes 
have resulted in various alterations of drug pharmacokinetics and multiple 
3 A 6 16 21 
studies have documented such effects. ' ' ' In addition, studies 
have reported changes in phenobarbital serum concentrations subsequent to 
18 22 
phenytoin administration, ' It was postulated by Morselli that pheny-
toin impairs the hydroxylation of phenobarbital or decreases its urinary 
18 
excretion. Therefore alterations of the plasma concentration of other 
drugs may occur secondary to the administration of either phenobarbital 
or phenytoin. However, a second concern is of major importance to the 
present study; such patient specific factors as drug half-life, elimina-
tion rate constant, total body clearance, and apparent volume of distribu-
tion were not determined. It was assumed without documentation that 
14 
children have an increased rate of elimination with phenobarbital and 
secondly that enhanced elimination implies a variable daily serum con-
centration. With the lack of pharmacokinetic data presented by Svensmark 
and Buchthal, it is difficult to accept this postulate and the suggestion 
for dosing phenobarbital. 
Data demonstrating an age dependent rate of phenobarbital elimina-
tion from the neonatal period to infancy were published by Heimann and 
Gladtke who postulated that the metabolic clearance was lower for new-
borns on a milligram per kilogram basis.^ They found that neonates have 
a phenobarbital half-life of 118 + 16 hours which decreases by six months 
of age to 6 3 + 4 hours, and suggested that maturity of the renal system 
accounted for this change. Jailing, et.al, evaluated phenobarbital 
pharmacokinetics in infants, in which the plasma phenobarbital concentra-
tion was measured in 33 infants aged 9 months to 2h years after single 
4 
doses of either oral or intramuscular phenobarbital were administered. 
Evaluation of these data revealed an average total body clearance for 
phenobarbital with single dose oral therapy of 0.0079 L/Kg/hr. The form-
ula used here is: Cl^ = k e X Vd where Cl^ , = total body clearance, k e = 
elimination rate constant, and V^ = apparent volume of distribution; each 
4 
of these values was presented in the data from the study. Jailing?s 
clearance calculation compares favorably with the data seen in Table 2 
from the present study and both values are nearly twice the clearance 
reported in adults, 0.004 L/Kg/hr."^ However, a more rapid elimination 
of a drug does not necessarily equate to a more variable daily serum 
level. This is supported by our data where no statistically significant 
difference was found between the two dosing regimens despite the enhanced 
15 
clearance. In considering the range of phenobarbital half-life reported 
for children, one can suggest the possibility of once daily dosing as is 
used in adult therapy. This premise may change in the clinical setting 
where multiple drug regimens and enhanced metabolism do occur '^'^' 1 6 - 2 1 
but with careful monitoring of serum blood concentrations interpatient 
variations can be adjusted. 
This investigation suggests the efficacy in maintaining therapeutic 
serum phenobarbital concentrations with once daily dosing. There was no 
statistically significant difference in the two regimens used for mainte-
nance of serum levels in these seven patients but the population was too 
small to draw firm conclusions. They were all maintained within either 
23 
the therapeutic range (defined as 15 mg/L to 40 mg/L) or within the 
limits of laboratory error if applied to their initial serum concentration. 
In addition, no patient developed adverse effects from this regimen and 
no seizure episode occurred, All parents stated that it was much easier 
to remember the once daily dose rather than the twice daily dose, the 
former regimen being more convenient. This agrees with the presumption 
24 25 
that a simplified dosing regimen may contribute to improved compliance. ' 
Although the investigation was unable to demonstrate differences in com-
pliance with the two regimens, this may be a result of the parents aware-
ness of drug administration because of the study design. Our results 
suggest that it may be appropriate to recommend once daily dosing with 
phenobarbital. This regimen contributed to convenience of administration 
and adequate control of serum concentrations in our study population. 
In seven pediatric patients with seizure disorders, aged eight 
months to seven years, a single daily dose of phenobarbital was as effec-
tive in maintaining therapeutic serum concentrations as twice daily dosing. 
16 
There were no adverse reactions to the daily regimen and no seizure 




PATIENT'S DAILY RECORD 
Date begun 
Date Time of dose Comments (seizures, infections, new meds) 
AM PM 
19 
Consent Form for Phenobarbital Study 
Efficacy of Once Daily Dosing with Phenobarbital 
We do not know if once daily or twice daily dosing with phenobarbi-
tal in seizure disorders is more effective. One dosing schedule may 
produce better control, therefore we are conducting a study to determine 
which schedule is better. Your child's physician has prescribed pheno-
barbital as primary therapy for his/her seizure disorder, therefore 
he/she has been invited to participate in this study. All children in 
the study will receive phenobarbital orally in two different schedules. 
The dose will be the same, but he/she will take all of it once in the 
morning or evening for 6-8 weeks, then he/she will be instructed to 
divide the dose in half, taking part in the morning and the other part 
in the evening for the same period of time as before. 
Each child will be followed closely in the Neurology Clinic at 
Primary Children's Medical Center or by his/her private physician to 
see if this change makes a difference in the control of his/her seizure 
disorder. Routine blood tests will be performed to be sure the level 
of phenobarbital is high enough. Because these tests are already a 
part of the regular routine in the clinic and by your physician, there 
are no additional risks with the blood tests. Benefits to your child 
from the study include detailed followup therapy by physicians and 
medical personnel and possibly a simplified dosing regimen. Participa-
tion in the study is completely voluntary and all information shall be 
kept confidential. 
I have approved my child's participation as an experimental sub-
ject in the above clinical research project. I understand the purpose 
of the project and its benefits, which have been fully explained to me. 
I have had fair opportunity to ask questions about the procedures. I 
understand that I am free to withdraw my consent and discontinue parti-
cipation in the project at any time without prejudice. 
Witness Name of Patient 




1. Buchthal F, Lennox-Buchthal MA: Phenobarbital-relation of serum 
concentration to control of seizures; in Woodbury DM, et,al.(Eds.): 
Antiepileptic Drugs, New York, Raven Press, 1972, pp.335-343. 
2. Livingston S: Medical treatment of epilepsy: Part I and II. South 
Med J 71(3) :298-310, Mar 1978; South Med J 71 (.4) :432-447, Apr 
1978. 
3. Garrettson LK, Dayton PG: Disappearance of phenobarbital and di-
phenylhydantoin from serum of children. Clin Pharmacol Ther 
11(5):674-679, Sep/Oct 1970. 
4. Jailing B: Plasma and cerebrospinal fluid concentrations of pheno-
barbital in infants given single doses. Dev Med Child Neurol 
16:781-793, Dec 1974. 
5. Heimann G, Gladtke E: Pharmacokinetics of phenobarbital in child-
hood. Eur J Clin Pharmacol 12C4):305-310, Dec 1977. 
6. Leal KW, Troupin AS: Clinical pharmacology of antiepileptic drugs: 
a summary of current information. Clin Chem 23(11):1964-1968, 
Nov 1977. 
7. Svensmark 0, Buchthal F: Accumulation of phenobarbital in man. 
Epilepsia 4:199-206, Dec 1963. 
8. Svensmark 0, Buchthal F: Dosage of phenytoin and phenobarbital in 
children. Dan Med Bull 10(8):234-235, Dec 1963. 
9. Svensmark 0, Buchthal F: Diphenylhydantoin and phenobarbital-
serum levels in children. Am J Pis Child 108:82-87, Jul 1964. 
10. Hvidberg EF, Dam M: Clinical pharmacokinetics of anticonvulsants. 
Clin Pharmacokinet 1(1):161-188, Jan/Feb 1976. 
11. Gibaldi M, Perrier D: Pharmacokinetics- Drugs and Pharmaceutical 
Sciences, Vol.1, New York, Marcel Dekker, 1975, p,28. 
12. Enzyme Immunoassay of Phenobarbital, Syva Product Information -
Emit-aed, 1977, Syva, Palo Alto, California. 
13. Greenblatt DJ, Koch-Weser J: Clinical pharmacokinetics^- Part I and 
II. N Engl J Med 293:702-705, 2 Oct 1975; N Engl J Med 293:964-
970, 6 Nov 1975. 
21 
14. Conney AH: Pharmacological implications of microsomal enzyme in-
duction. Pharmacol Rev 19:317-366, Sep 1967. 
15. Klaassen CD: Biliary flow after microsomal enzyme induction. 
J Pharmacol Exp Ther 168:218-223, Aug 1969, 
16. Buchanan RA, Heffelfinger JC, Weiss CF: The effect of phenobarbital 
on diphenylhydantoin metabolism in children. Pediatrics 43:114-
116, Jan 1969. 
17. Cucinell SA: Phenobarbital-interactions with other drugs; in 
Woodbury DM et.al.(Eds.): Antiepileptic Drugs, New York, Raven 
Press, 1972, pp.319-327. 
18. Morselli PL, Rizzo M, Garattini S: Interaction between phenobarbital 
and diphenylhydantoin in animals and in epileptic patients. Ann 
NY Acad Sci 179:88-107, Jul 1971. 
19. Pitlick W, Painter M, Pippenger C: Phenobarbital pharmacokinetics 
in neonates. Clin Pharmacol Ther 23:346-350, Mar 1978. 
20. Rane A, Wilson JT: Clinical pharmacokinetics in infants and child-
ren. Clin Pharmacokinet 1(1):2-24, Jan/Feb 1976. 
21. Travers RD, Reynolds EH, Gallagher BB: Variation in response to 
anticonvulsants in a group of epileptic patients. Arch Neurol 
27:29-33, Jul 1972. 
22. Lambie DG, et.al.: Therapeutic and pharmacokinetic effects of in-
creasing phenytoin in chronic epileptics on multiple drug therapy 
Lancet 2(7982):386-389, 21 Aug 1976. 
23. Feldman RG, Pippenger CE: The relation of anticonvulsant drug levels 
to complete seizure control. J Clin Pharmacol 16(.1) :51-59, Jan 
1976. 
24. Boyd JR, et.al.: Drug defaulting: determinants of compliance. Am J 
Hosp Pharm 31:362-367, Apr 1974. 
25. Boyd JR, et.al.: Drug defaulting: analysis of noncompliance patterns 
Am J Hosp Pharm 31.: 485-491, May 1974. 
CURRICULUM VITAE 






638 J Street 
Salt Lake City, Utah 84103 
Telephone (801) 521-5440 
Department of Pharmacy Practice 
College of Pharmacy 
University of Utah 
Salt Lake City, Utah 84112 
Telephone (801) 581-5941 
January 20, 1952 
Raleigh, North Carolina 
Single 
None 
AVAILABLE FOR POSITION: July 1980 
LICENSURE: North Carolina (September 1975) 
Florida (January 1976) 
Colorado (September 1977) 
PROFESSIONAL GOALS AND OBJECTIVES: 
To initiate and maintain professional competency in an academic 
or private institution as a practitioner-educator in the profession 
of pharmacy. To provide services exemplary of an interdisciplinary 
approach to total patient care with special emphasis in pediatrics. 
To contribute to the profession through research in pertinent areas 
of my practice and using this as an aide to continue professional 
competency. 
EDUCATIONAL BACKGROUND: 
1978 - present Doctor of Pharmacy Program 
University of Utah 
College of Pharmacy 
Salt Lake City, Utah 
Expected graduation: June 1980 
Advisor: John A. Bosso, Pharm.D. 
23 









Bachelor of Science in Pharmacy 
University of North Carolina 
College of Pharmacy 
Chapel Hill, North Carolina 
Clerkship Duration 
Internal Medicine 6 months 
Surgery 1.5 months 
Infectious Disease 1.5 months 
Adult Psychiatry 1.5 months 
Pediatrics 3 months 
Neonatology 1.5 months 
Pediatric Nephrology 1.0 month 
Pediatric Cardiology 1.0 month 
Pediatric Neurology 1.5 months 
Pediatric Psychiatry 1.0 month 
Pediatric Nutrition 1.0 month 
Drug Information 1.5 months 
Ambulatory Care 1.5 months 
Mary E. Russo, Pharm.D. 
John Russo, Jr., Pharm.D. 
Jean D. Devenport, Pharm.D. 
Linda L. Hart, Pharm.D. 
John A. Bosso, Pharm.D. 
Kelly D. Mutchie, Pharm.D. 
Martin D. Higbee, Pharm.D. 
George E. Dukes,Jr., Pharm.D. 
Thomas C. Sudds, Pharm.D. 
Teaching Assistant 
Baccalaureate Instruction 
University of Utah 
College of Pharmacy 
Salt Lake City, Utah 
Drug Information Center Technician 
Department of Hospital Practice 
University of Utah Medical Center 
Salt Lake City, Utah 
24 








Assistant Pharmacist Manager 
The Pharmaticque 
Englewood, Colorado 
Assistant Pharmacist Manager 
Pharmacy Intern 
Kerr Drug Stores, Inc. 
Raleigh, North Carolina 
Pharmacy Extern 
North Carolina Memorial Hospital 
University of North Carolina 
Chapel Hill, North Carolina 
PROFESSIONAL SOCIETIES: 
American Society of Hospital Pharmacists 
Colorado Pharmacal Association (past) 
North Carolina Pharmaceutical Association (past) 





Student Advisory Committee 
Pharm.D. Candidates' Representative 
University of Utah 
College of Pharmacy 
Salt Lake City, Utah 
Journal Club 
University of Utah 
College of Pharmacy 
Salt Lake City, Utah 
Pharmacist Counselor 
Camp UTADA 
Utah Diabetic Association 
Summer Camp for Diabetic Children 
Salt Lake City, Utah 
Curriculum Committee 
Pharm.D. Candidates' Representative 
University of Utah 
College of Pharmacy 
Salt Lake City, Utah 
25 
AWARDS AND HONORS: 
1975 
1974-1975 
Rho Chi Achievement Award 
Pharmacy Honor Society 
University of North Carolina 
College of Pharmacy 
Chapel Hill, North Carolina 
School of Pharmacy Scholarship 
University of North Carolina 
College of Pharmacy 
Chapel Hill, North Carolina 
RESEARCH IN PROGRESS: 









University of Utah 
College of Pharmacy 
Salt Lake City, Utah 
Topic: Management of Chronic Obstructive 
Pulmonary Disease 
Pathophysiology and Pharmacotherapeutics 
University of Utah 
College of Pharmacy 
Salt Lake City, Utah 
Topic: Chronic Bronchitis and Emphysema 
Utah Pharmaceutical Association 
First Annual Mid Year Conference 
University of Utah 
College of Pharmacy 
Salt Lake City, Utah 
Topic: Critical Reviews of New Drugs 
Division of Psychiatry 
Staff Conference 
Veterans Administration Hospital 
Salt Lake City, Utah 
Topic: Lithium Therapy 
Rocky Mountain Gerontology Center 
Staff Conference 
Salt Lake City, Utah 
Topic: Diabetes Mellitus 
